Print Page   |   Contact Us   |   Your Cart   |   Sign In
Search
Sign In
Sign In securely
Breaking News
Calendar

6/22/2017 » 6/25/2017
2017 OSAP Annual Conference

News & Press: Daily Updates

MMWR: Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influ

Thursday, April 28, 2016   (0 Comments)

On January 14, 2016, GlaxoSmithKline Biologicals (Research Triangle Park, North Carolina) received approval from the Food and Drug Administration (FDA) to expand use of Hiberix (Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]) for a 3-dose infant primary vaccination series at ages 2, 4, and 6 months.

MORE >>


OSAP Disclaimer | Please notify our webmaster of any problems with this website.
OSAP thanks its Super Sponsors for their support in 2017. Sponsorship does not imply endorsement by OSAP of a company's products or services.